





# Session 12: CLINICAL GUIDELINES, ESSENTIAL LISTS Noncommunicable Diseases

UNICEF, UNFPA and WHO meeting with manufacturers and suppliers, 27 November-01 December 2023, Copenhagen, Denmark

Dr Slim Slama

Unit Head, Noncommunicable Diseases Management-Screening, Diagnosis and Treatment (MND)

NCD Department

World Health Organization

email: slamas@who.int







# CANCER







## Levers in access to oncology medicines including market shaping



Policy in National cancer control plans (NCCP) coherent with National Essential Medicines Lists (nEML) and treatment guidelines.

WHO activities supporting access to medicines along the value chain including



Procurement, pricing and financing strategies are in place to ensure sustainable access.



- Prequalification
- Regulatory approval pathways
- Supply chain strengthening
- National standard development
- Safe handling of chemotherapy



Regulatory affairs are supported, including pharmacovigilance, to ensure safe distribution and use of medicines.







# Global Platform for Access to Childhood Cancer Medicines

Announced with St Jude Children's Research Hospital and partnering with UNICEF and PAHO Strategic Fund

Platform vision: a **comprehensive** solution engaging **global partners** to provide an **uninterrupted** supply of **quality** childhood cancer medicines

	Development Phase	Pilot I	Phase	Growth Phase			
	2022	2023	2024	2025	2026	2027	
Countries		6	12	30	40	50	
Children		5,000	12,000	25,000	35,000	45-50,000	
Budget (USD)	2 million	11 million	21 million	39 million	50 million	65 million	

- \* 50,000 children per year by 2027 represents approximately:
  - 25% of all children with cancer in the world
  - 30% of children with cancer in low and middle-high income countries
  - 60% to 70% of children with cancer in low and lower-middle income countries

By 2027, the Global Platform will have provided medications for more than 120,000 children










#### WHO Cervical cancer elimination

Global strategy including through increased access to essential health products







### **Secondary Prevention**

#### Guidance

Updated guidelines for screening and treatment with promotion HPV test



#### Global strategy to accelerate the elimination of cervical cancer as a public health problem





### Access to HPV test

- (1) WHO HPV test PQ (4<sup>th</sup> test approved),
- (2) Private sector dialogue with "asks" and focus on HPV Test
- (3) TPP for HPV test
- (4) Procurement support for 5+ countries

Also, emerging innovation (therapeutic vaccine)









# **ORAL HEALTH**








### **Dental Medicines and Preparations**

- Silver diamine fluoride (SDF)
- Glass ionomer cement
- Fluoride toothpaste

	SDF			Glass ionomer cement			Fluoride toothpaste		
	ACER	An. HLYG per million	An. Cost per million (\$)	ACER	An. HLYG per million	An. Cost per million (\$)	ACER	An. HLYG per million	An. Cost per million (\$)
LIC	1343	547	734647	770	621	478334	27	142	3813
LMIC	2753	562	1547176	1199	655	785675	17	137	2395
UMIC	5520	561	3097033	1773	644	1142109	37	142	5312



Untreated tooth decay affects
2.5 billion people